Dichiarazione di accessibilità Salta la navigazione
  • Torna ai siti globali
  • +44 (0)20 7454 5110
  • GDPR
  • Giornalisti
  • Richiedi maggiori informazioni
PR Newswire: news distribution, targeting and monitoring
  • Notizie
  • Prodotti
  • Contatto
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Richiedi maggiori informazioni
    • Telefono

    • +44 (0)20 7454 5110 da 8 AM - 5 PM GMT

    • Contattaci
    • Contattaci

      +44 (0)20 7454 5110
      da 8 AM - 5 PM GMT

  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR

Menarini Diagnostics CoronaMeltVAR Real-Time PCR kit simultaneously detects SARS CoV-2 and identifies the Omicron Variant
  • USA - español
  • USA - English
  • Italia - Italiano
  • Latin America - español
  • Brazil - Português
  • USA - Deutsch
  • USA - Français

Menarini Logo

Notizia fornita da

Menarini Industrie Farmaceutiche Riunite

17 gen, 2022, 13:52 GMT

Condividi articolo

Share toX

Condividi articolo

Share toX

FLORENCE, Italy, Jan. 17, 2022 /PRNewswire/ -- The new Omicron variant is spreading rapidly causing an increase in infections at unprecedented speed. On November 28th, WHO officially recommended laboratories to use Real Time PCR detection kits capable of identifying putative Omicron variant infections, directly at the moment of the positivity test.

To support this recommendation, Menarini offers CoronaMeltVAR, a CE-IVD Real-Time PCR kit based on intercalating dye and melting curve analysis. The kit detects positive samples with high sensitivity, through the amplification of two targets, both compatible with all variants and with the wild type form, simultaneously revealing with distinct signals the suspect presence of Omicron Variant BA.1, BA.2, as well as Alpha, Beta/Gamma and WT/Delta.

All responses are obtained in a single run on each sample, with no loss of sensitivity compared to normal kits and without the need to perform a second reflex test on positive samples. The kit is compatible with most RNA extraction protocols and Real-Time PCR instruments capable of performing melting curve analysis at moderate resolution. CoronaMeltVAR provides SARS CoV-2 CE IVD detection and Omicron surveillance in less than 2 hours.

"We are extremely proud to have made this unique solution available so quickly. It is helping healthcare professionals in providing a specific, rapid and accurate solution for the diagnosis and identification of Covid-19 Omicron variant", said Fabio Piazzalunga, General Manager & Global Head of A.Menarini Diagnostics and Chairman/CEO of Menarini Silicon Biosystems.

A.Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world.

A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, it counts more than 17,000 employees and has a 2020 turnover of € 3.750 billion.

www.menarinidiagnostics.com

Logo: https://mma.prnewswire.com/media/1584634/Menarini_Logo.jpg

Modal title

Sempre da questa fonte

Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025

Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025

Il Gruppo Menarini ("Menarini"), azienda leader a livello internazionale nel settore farmaceutico e diagnostico, e Stemline Therapeutics, Inc....

Il Gruppo Menarini annuncia che, al 67° Congresso Annuale dell'American Society of Hematology, presenterà nuovi dati su ELZONRIS® (tagraxofusp-erzs)

Il Gruppo Menarini annuncia che, al 67° Congresso Annuale dell'American Society of Hematology, presenterà nuovi dati su ELZONRIS® (tagraxofusp-erzs)

Il Gruppo Menarini ("Menarini"), azienda leader a livello internazionale nel settore farmaceutico e diagnostico, e Stemline Therapeutics, Inc....

Altri comunicati stampa da questa fonte

Esplora

Health Care & Hospitals

Health Care & Hospitals

Medical Equipment

Medical Equipment

Medical Pharmaceuticals

Medical Pharmaceuticals

Infection Control

Infection Control

Comunicati stampa su argomenti simili

Contatta PR Newswire

  • +44 (0)20 7454 5110
    da 8 AM - 5 PM GMT

Siti globali

  • APAC
  • APAC - Cinese tradizionale
  • Asia
  • Brasile
  • Canada
  • Ceco
  • Danimarca
  • Finlandia
  • Francia
  • Germania

 

  • India
  • Indonesia
  • Israele
  • Italia
  • Messico
  • Medio Oriente
  • Medio Oriente - Arabo
  • Olanda
  • Norvegia
  • Polonia

 

  • Portogallo
  • Russia
  • Slovacchia
  • Spagna
  • Svezia
  • Regno Unito
  • Stati Uniti

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Siti globali
  • Asia
  • Brasile
  • Canada
  • Ceco
  • Danimarca
  • Finlandia
  • Francia
  • Germania
  • India
  • Israele
  • Italia
  • Messico
  • Medio Oriente
  • Olanda
  • Norvegia
  • Polonia
  • Portogallo
  • Russia
  • Slovacchia
  • Spagna
  • Svezia
  • Regno Uniti
  • Stati Uniti
+44 (0)20 7454 5110
da 8 AM - 5 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.